Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Ningning Zhang; Tian Liu; Ming Luo; Jihui Hao; Shukui Qin; Yanqiao Zhang; Gang Wang; Yajin Chen; Jingdong Zhang; Shanzhi Gu; Junqi Niu; Guijie Xin; Ge Yu; Yabing Guo; Chongyuan Xu; Jun Yao; Jie Shen; Aibing Xu; Shuwen Zhang; Di Yang; Meijuan Gao; Ruixuan Luo; Yanxia He; Fei Zheng; Nan Cao; Xiaolu Tao

doi:10.1158/1078-0432.29760314

Key Points

MAIN FINDING: Toripalimab demonstrates promising results as a second-line therapy for advanced hepatocellular carcinoma.
KEY EVIDENCE: The multicenter, open-label trial reports improved outcomes in progression-free survival and overall survival.
APPROACH: This study involved multiple centers and a phase I trial design to evaluate the therapy's effectiveness.
SIGNIFICANCE: These findings suggest that toripalimab may become a valuable treatment option for patients with advanced hepatocellular carcinoma.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Multicenter trial shows improved progression-free survival and overall survival with toripalimab in advanced hepatocellular carcinoma, indicating its potential as an effective second-line therapy.

Abstract

Supplementary Figure S4. The PFS and OS curves.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d01db https://doi.org/10.1158/1078-0432.29760314

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers